Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755911 | 0.95 | AR (0.40) | ARPIN1CACNA1HMCHR1EGLN1 | |
| SCHEMBL20096687 | 0.76 | CACNA1H (0.41) | ARCACNA1HTRPA1 | |
| SCHEMBL20096569 | 0.76 | CACNA1H (0.41) | ARCACNA1HTRPA1 | |
| SCHEMBL1260022 | 0.74 | CACNA1H (0.37) | ARCACNA1HTRPA1 | |
| SCHEMBL1259264 | 0.73 | EGLN1 (0.54) | AREGLN1 | |
| SCHEMBL5191162 | 0.70 | EGLN1 (0.44) | AREGLN1 | |
| SCHEMBL1259840 | 0.70 | EGLN1 (0.46) | AREGLN1 | |
| SCHEMBL1636643 | 0.69 | AR (0.56) | ARCACNA1HTRPA1 | |
| SCHEMBL1260113 | 0.69 | EGLN1 (0.43) | ARPIN1EGLN1 | |
| SCHEMBL1636551 | 0.69 | AR (0.44) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-30 | — | — | US | disclosed |
| US-8575206-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-05 | — | — | US | disclosed |
| EP-1984343-B1 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| EP-1984343-A2 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | Janssen Pharmaceutica, N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007087518-A2 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PIN1 2600/4885CACNA1H 4193/4885 |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PIN1 2600/4885CACNA1H 4193/4885 |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PIN1 2600/4885CACNA1H 4193/4885 |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | AR 1/4885PIN1 2600/4885CACNA1H 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.